Please upgrade your browser.
Education and support for families dealing with renal malignancies
We conducted a phase I/II trial to determine the safety and efficacy of infliximab in combination with sorafenib in patients with advanced RCC.
Many studies have demonstrated the strong correlation between HA accumulation and presence of malignancy in numerous solid tumor types, including genitourinary cancers.
"The results might suggest new ways to combine AurA inhibitors with other drugs to boost their activity," says Erica A. Golemis, Ph.D.
Sutent is an oral targeted agent that works by inhibiting multiple biologic pathways involved in the growth, replication, and spread of cancer cells. It has been shown to be effective in the treatment of selected patients with kidney cancer or gastrointestinal stromal tumors, and is also being evaluated in the treatment of other types of cancer.
239 patients died of malnutrition in British hospitals, the latest year for which figures are available . . . the real roots of this tragedy lie in Britain's government-run medical system, which tells us something about what we might expect from ObamaCare in the years ahead.
We now report long-term survival of 4 patients with stage IV sarcomatoid renal cell carcinoma treated with this regimen . . .
The patient had stable disease after 8 weeks (two cycles) of everolimus that was maintained until 28 months of therapy, at which time the patient had achieved a partial response. This case illustrates the potential for patients with metastatic renal cell carcinoma, a malignancy with historically poor prognosis, to derive long-term benefit from everolimus when used in a manner consistent with its approved indication (after TKI therapy with sunitinib or sorafenib).
Wilms' tumor is a rare childhood form of kidney cancer also known as nephroblastoma. Only about five in a million American children will be diagnosed with Wilms' tumor each year, mostly around age 3, but 10% of those children will die within five years of their diagnosis. For this reason, as with all cancers, it is important to catch the disease and begin treatment as early as possible.
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
Serum interleukin (IL)-6 levels correlate with disease outcomes in renal cell carcinoma (RCC) patients. Siltuximab, a chimeric, murine-human mAb against IL-6, was evaluated in a three-part phase I/II study in patients with progressive metastatic RCC.
|Powered by NeonCRM|